Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osugacestat - Ayala Pharmaceuticals

Drug Profile

Osugacestat - Ayala Pharmaceuticals

Alternative Names: AL-101; BM-0018; BMS-906024

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors; Notch receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenoid cystic carcinoma; Triple negative breast cancer
  • Clinical Phase Unknown Fibroma
  • No development reported Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours; T-cell lymphoma

Most Recent Events

  • 07 Feb 2024 Immunome acquires AL 101 from Ayala Pharmaceuticals
  • 20 Oct 2023 Final adverse events and efficacy data from the phase-II ACCURACY trial in Adenoid cystic carcinoma presented at the European Society for Medical Oncology Congress (ESMO-2023)
  • 02 Dec 2022 Ayala Pharmaceuticals completes phase II trial in Adenoid cystic carcinoma (Metastatic disease, Recurrent, Late-stage disease) in Netherlands, United Kingdom, Israel, France, USA and Canada (IV) (NCT03691207)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top